$13.89
+0.31 (+2.28%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where WW is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Balyasny Asset Management L.P.) · FINRA short interest 14.3 days to cover (settled 2026-07-31) · insider 90d: 6 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)NCT06605703Percent body weight change at 12 weeksRandomized · Single-masked · Treatment | Phase 4 | Completed | Behavioral: WW Clinic · Drug: Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin | Obesity, Overweight | 226 | 2026-02-05actual | 2026-04-13 |
| A Randomized Controlled Trial Comparing the Efficacy of Commercial Weight Management ProgramsNCT06972277Percent body weight lost at 12 weeksRandomized · Single-masked · Treatment | Not applicable | Completed | Behavioral: Commercial weight management program | Obesity and Overweight | 459 | 2026-01-09actual | 2026-04-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19